Compare INTT & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTT | MGNX |
|---|---|---|
| Founded | 1981 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.8M | 115.8M |
| IPO Year | 1997 | 2013 |
| Metric | INTT | MGNX |
|---|---|---|
| Price | $14.15 | $3.04 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 5 |
| Target Price | ★ $14.00 | $3.40 |
| AVG Volume (30 Days) | 135.1K | ★ 1.3M |
| Earning Date | 06-02-2026 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $66,801,000.00 | ★ $149,500,000.00 |
| Revenue This Year | $13.07 | N/A |
| Revenue Next Year | $6.52 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 66.06 | N/A |
| 52 Week Low | $5.24 | $0.99 |
| 52 Week High | $15.01 | $3.50 |
| Indicator | INTT | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 72.36 | 72.48 |
| Support Level | $7.21 | $1.45 |
| Resistance Level | $15.01 | $3.50 |
| Average True Range (ATR) | 0.96 | 0.22 |
| MACD | 0.09 | 0.08 |
| Stochastic Oscillator | 83.07 | 74.26 |
inTest Corp is a supplier of test and process solutions for use in manufacturing and testing across a range of markets including automotive, defense/aerospace, industrial, medical, semiconductor and telecommunications. The company manages its business as three operating segments which is also their reporting units that includes Electronic Test, Environmental Technologies and Process Technologies. Electronic Test (which includes semiconductor test equipment, flying probe and in-circuit testers), Environmental Technologies (which includes its thermal test, process and storage products) and Process Technologies (which includes induction heating and video imaging products). The company operates their business and sells its products both domestically and internationally.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.